Your father and brother had aggressive prostate cancer. You're wondering if it's your inheritance. Before it develops, you could know.
Whole genome sequencing identifies hereditary prostate cancer variants in BRCA2, HOXB13, and ATM — enabling early screening that can catch cancer at earlier, more treatable stages.
Hereditary Prostate Cancer
Hereditary prostate cancer encompasses multiple distinct genetic predisposition pathways. BRCA2 carriers face 3–8-fold increased prostate cancer risk, with significantly more aggressive disease. The HOXB13 G84E variant is far more penetrant — conferring up to a 20-fold increased risk of hereditary prostate cancer, particularly among men of European ancestry. ATM pathogenic variants increase risk approximately 2–3-fold, with additional pancreatic cancer risk implications. All three genes function in DNA damage response: BRCA2 and ATM mediate DNA repair signaling; HOXB13 is a transcription factor essential for prostate development — each represents a distinct biological pathway to cancer susceptibility.
Hereditary prostate cancer accounts for 5–15% of prostate cancer cases overall, with significantly higher heritability estimates than most common cancers. HOXB13 G84E carriers represent 0.6–6.25% of hereditary prostate cancer cases in European populations. BRCA2 variants occur in 1.2–5.3% of hereditary prostate cancer families, ATM in 1.6–2.7%, and CHEK2 in 1.8–2.8%. Carriers tend to develop prostate cancer at younger ages (median age 55–60 vs. 65–70 in non-hereditary disease) with more aggressive Gleason scores and metastatic potential. Approximately 50% of men with a family history of prostate cancer carry a pathogenic variant in one of these genes.
Identifying the specific genetic cause has profound clinical implications. A BRCA2 finding qualifies men for PSA screening from age 40 and, if cancer develops, eligibility for PARP inhibitor therapy (olaparib) — a genotype-targeted therapy that produces durable responses in men with BRCA2-associated castration-resistant prostate cancer. An HOXB13 finding enables early screening and intensified family surveillance. All discoveries cascade to relatives: brothers can begin early screening to prevent or detect cancer earlier; sisters may carry the same variant and have breast/ovarian cancer risk (particularly BRCA2).
The three major hereditary prostate cancer genes operate through distinct biological mechanisms — BRCA2 and ATM in DNA repair signaling, HOXB13 in prostate development — each conferring different cancer aggressiveness and screening intervals.
Prostate cancer has been historically under-tested genetically. BRCA2-only testing misses HOXB13 and ATM — genes that together account for significant hereditary disease.
Standard prostate panels often miss the culprit genes
Hereditary prostate cancer testing lags significantly behind breast and colorectal cancer testing. Many commercially available hereditary cancer panels were designed for breast/ovarian cancer and do not include HOXB13. Single-gene BRCA2 testing misses ATM and CHEK2 contributions. Across hereditary prostate cancer families, HOXB13 accounts for 0.6–6.25% of cases, BRCA2 for 1.2–5.3%, ATM for 1.6–2.7%, and CHEK2 for 1.8–2.8%. No single-gene or limited-panel approach captures the full genetic landscape. Whole genome sequencing reads all prostate cancer predisposition genes simultaneously.
A genetic finding opens targeted therapy and family prevention
BRCA2 carriers with metastatic prostate cancer are eligible for PARP inhibitor therapy (olaparib) — one of the few genotype-matched treatments in prostate cancer oncology. An HOXB13 G84E finding enables aggressive early PSA screening from age 40 in at-risk men. ATM findings inform pancreatic cancer surveillance for male carriers with family history. All findings trigger cascade testing: brothers can begin early PSA screening before cancer develops; sisters may carry the same variant and qualify for breast/ovarian cancer surveillance.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Hereditary Prostate Cancer and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We’ll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
